Advanced Treatment Options for RA: Exploring the Data

EP: 1.Intro and Welcomes

EP: 2.Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP: 3.Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP: 4.Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP: 5.Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP: 6.Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP: 7.Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP: 8.Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

Now Viewing

EP: 9.Advanced Treatment Options for RA: Exploring the Data

EP: 10.Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP: 11.JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP: 12.JAK Inhibitor Selectivity and Dose-Related Toxicity

Video content above is prompted by the following:

Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission.

• Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab.
• Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial).
• What are the remission rates seen with upadacitinib vs abatacept (SELECT-CHOICE trial)?